Basics
Dr. Ravi Vij - Founder @mycancerhaven Discussing With Jonathan L. Kaufman MD on Xpovio
Dr. Ravi Vij, Discussing With Muhamed Baljević, on Novel Treatment Options Beyond BCMA Therapies
Dr. Ravi Vij Discussing With Craig C. Hofmeister MD, MPH on Immunomodulatory Drugs
Dr. Ravi Vij Discussing with Craig Emmitt Cole, MD on How to Interpret Your Test Results
Dr. Ravi Vij Discussing with Brea Lipe MD, on Multiple Myeloma: Relapsed Disease
Dr. Ravi Vij Discussing With Keith E. Stockerl-Goldstein, MD on Amyloidosis
Dr. Ravi Vij Discussing with Prashant Kapoor M.D. on MGUS and Smoldering Myeloma
Dr. Ravi Vij Discussing with Dr. Melissa Alsina on High Risk Myeloma
Dr. Ravi Vij Discussing on Peripheral Neuropathy with Dr. Beth Faiman
Dr. Ravi Vij Interviews Dr. Joshua Richter on Autologous Stem Cell Transplantation
Dr. Ravi Vij Discussing with Dr. Adriana Rossi MD on Measurable Residual Disease (MRD)
Watch Dr Luciano Costa Discuss Therapy for Relapsed Multiple Myeloma with Dr. Ravi Vij
Multiple Myeloma Introduction with Dr. Shaji Kumar | Professor of Medicine
Multiple Myeloma Initial Treatment and Monitoring by Dr. Ajay Nooka MD MPH
Dr. Ravi Vij, Discussing with Dr. Andrew Yee MD, on Bispecific Antobodies for Multiple Myeloma
Dr Ravi Vij Discussing with Dr. Larry Anderson, M.D., Ph.D. on #tecvayli (Teclistamab)
Dr. Ravi Vij Discussing With Dr. Craig C. Hofmeister MD on Immunomodulatory Drugs
Dr. Ravi Vij Discussing With Jonathan L. Kaufman MD on Xpovio (Selinezor)
Dr. Ravi Vij, Discussing with Sikander Ailawadhi, M.D. on Proteosome Inhibitors
Dr. Ravi Vij Discussing With Dr. Scott R. Goldsmith, MD on Monoclonal Antibodies
Ravi Vij in Discussion with Dr. Nitya Nathwani MD, on Choosing B/w CAR-Ts & Bispecific Antibodies
Advanced
Patterns of Practice in Relapsed Multiple Myeloma
Dr. Ravi Vij, MD is Discussing With Mr. Brian McMahon, Founder of SparkCures
Updates from American Society of Hematology Bispecifics with Dr. Peter Voorhees
Updates from American Society of Hematology 2022 Meeting with Dr. Jeffrey Zonder, M.D. | CAR-T Cells
Watch Dr Ravi VIj and Dr Gurbakhash Kaur discuss Talquetamab approved for multiple myeloma
Dr. Ravi Vij Discussing With Dr. Mark A Schroeder MD MSCI on Clinical Trials
Dr. Ravi Vij Discussing with Dr. Krina Patel MD on Moving CAR-T Earlier
Dr. Ravi Vij Discussing with Dr. Sham Mailankody, MBBS on Novel CAR-T Cells
Ravi Vij in Discussion with Dr. Binod Dhakal MD, on Managing Patients Long Term Post CAR-T
Ravi Vij in Discussion With Dr. Suresh Balasubramanian, M.D on Treating the Low Risk MDS
Ravi Vij in Discussion with Dr. Susan Bal, on Treating Triple Class Refractory Multiple Myeloma
Ravi Vij, in Discussion with Dr. Cristina Gasparetto, MD on Using Selinexor in her Pratice
Ravi Vij in Discussion with Dr. Tom Martin MD, on How the Pegasus & Iskia Trials Inflenced
Ravi Vij, in Discussion with Dr. Joshua Richter MD, on Managing the Side Effects of Talquetamab
Ravi Vij in Discussion with Dr. Al-Ola A Abdallah, MD on Using CAR-T Cells Post 1st Relapse in MM
Will CAR-Ts & Bispecifics elminate HSCT for Multiple Myeloma? Ravi Vij with Dr. Samer Al Hadidi MD
Ravi Vij, in Discussion with Dr. Sascha Alexander Tuchman, MD On Managing M-Myeloma In The Elderly
Multiple Myeloma: Ready for the Return of Belantamab Mafadotin?
Ravi Vij, in Discussion with Dr. Adriana Rossi MD: on ISTUXIMAB For Transplant ineligible Patients
Ravi Vij, in Discussion with Dr. Saad Z. Usmani, On The Phase 3 CEPHEUS Study
Ravi Vij, Discussing with Dr. Surbhi Sidana On Relapsed/Refractory Multiple Myeloma (RRMM) for RWE
Ravi Vij, in Discussion with Dr. Ashraf Badros MD, On The Phase 3 AURIGA Study
Ravi Vij, in Discussion with Dr. Ashraf Badros MD, On The Phase 3 AURIGA Study
